Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
A strong index level often signals robust momentum and potential persistence. Interpret carefully to adjust positions and risk exposure.
24,663 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Micron stock has jumped this year but pulled back in early 2026. Analysts say the AI memory demand cycle could push M...
Goldman Sachs raises price targets on three major tech names by roughly 10%, reflecting improved growth visibility as...
Traders eye a clearer long-run path for algorand as the network scales DeFi apps and CBDC pilots. This report outline...
AI adoption is accelerating, pushing leaders to redefine value beyond raw output. This shift reshapes careers and per...
BNB Chain unveils the BNBAgent SDK, the first live implementation of ERC-8183, enabling trustless, autonomous AI work...
Rivian shares surged about 8% after the company unveiled the R2 midsize SUV, signaling a push toward broader market a...
Deutsche Bank revealed a $30 billion private credit exposure, roughly 2.1% of its asset base, triggering a stock pull...
Cursor, valued near $29 billion, stands at the center of a fast-moving AI coding boom. The company faces intense grow...
A wave of autonomous AI agents is entering consumer finance, promising smarter budgeting and investing. Yet reliabili...
Chewy rode a brighter sales outlook to a rally in its stock, with the company signaling durable demand for pet care d...
Shield AI just unveiled a landmark Series G round worth $1.5 billion, lifting its valuation to $12.7 billion and sett...